Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Denosumab in breast cancer
Allan Lipton
Department of Medicine
Penn State Cancer Institute
Division of Hematology and Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Denosumab in breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Breast Cancer
100%
Denosumab
100%
Bone Destruction
66%
Osteoclast
66%
Receptor
66%
Malignant Neoplasm
33%
Zoledronic Acid
33%
Bone Metastasis
33%
Adverse Event
33%
Overall Survival
33%
Human Monoclonal Antibody
33%
Disease Exacerbation
33%
Bone Disease
33%
Immunology and Microbiology
Osteoclast
66%
Overall Survival
33%
Human Monoclonal Antibody
33%
Keyphrases
Bone Block
33%